Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

Source :: Plus Company Updates. June 20, 2017
Publication Year :: 2017
Abstract: Madrid, Spain: Pfizer has issued the following press release: Pfizer Inc. (NYSE: PFE)and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing in the research and development of anti-infective and [...]

Subjects :: Pfizer Inc.
Immunocompromised host -- Care and treatment -- Health aspects
Mycoses -- Care and treatment -- Health aspects
Antifungal agents -- Health aspects
Infection -- Care and treatment -- Health aspects
Industrial research -- United States -- Health aspects
Pharmaceutical industry -- Health aspects
Research and development
General interest
News, opinion and commentary
Cresemba (Medication) -- Health aspects

Tools